Neuropathix, Inc. Appoints Michael Ropacki to its Scientific Advisory Board
August 12, 2021 at 10:30 am EDT
Neuropathix, Inc. appointed pharmaceutical and biotechnology industry veteran Michael Ropacki, PhD to the Company's Scientific Advisory Board. Dr. Ropacki is currently the Chief Medical Officer of CNS Clinical and Product Development for Oryzon, as well as their US Site Head. He was previously Senior Vice President of Psychiatry Clinical Development at MedAvante-ProPhase. Prior to that, he held roles of increasing responsibility at Johnson &Johnson, his last as Director, Clinical Research Neuroscience, Research and Development, for Janssen Research &Development where he was responsible for leading the Cognitive Health in Aging Registry: Investigational, Observational and Trial studies in dementia research - Prospective Readiness Cohort (CHARIOT-PRO) program.